BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States Pharmaceutical Investing
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pharmaceutical Investing
Johnson & Johnson's Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022 Pharmaceutical Investing
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine Pharmaceutical Investing
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance Pharmaceutical Investing
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States Pharmaceutical Investing
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer Life Science Investing
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 Pharmaceutical Investing
